World Investment Advisors LLC Purchases Shares of 35,066 DexCom, Inc. (NASDAQ:DXCM)

World Investment Advisors LLC bought a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 35,066 shares of the medical device company's stock, valued at approximately $2,351,000.

Several other institutional investors also recently made changes to their positions in the stock. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in DexCom in the second quarter valued at $25,000. Sachetta LLC grew its stake in DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company's stock valued at $27,000 after acquiring an additional 171 shares during the last quarter. Riverview Trust Co increased its holdings in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock valued at $31,000 after acquiring an additional 232 shares in the last quarter. DT Investment Partners LLC raised its position in DexCom by 492.2% during the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company's stock worth $43,000 after acquiring an additional 315 shares during the last quarter. Finally, RPg Family Wealth Advisory LLC purchased a new stake in shares of DexCom in the third quarter valued at about $57,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Piper Sandler restated an "overweight" rating and set a $90.00 price objective on shares of DexCom in a research report on Monday, August 26th. Canaccord Genuity Group boosted their price target on DexCom from $89.00 to $99.00 and gave the stock a "buy" rating in a report on Monday, December 9th. Sanford C. Bernstein increased their price objective on DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a research note on Friday, October 25th. Oppenheimer cut their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. Finally, Stifel Nicolaus raised their price target on shares of DexCom from $90.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, August 23rd. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, DexCom presently has a consensus rating of "Moderate Buy" and a consensus target price of $98.00.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.30% of the company's stock.

DexCom Stock Down 2.2 %

NASDAQ DXCM traded down $1.74 on Friday, reaching $77.19. The company had a trading volume of 2,956,879 shares, compared to its average volume of 3,884,590. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The firm has a 50-day moving average of $73.76 and a 200-day moving average of $84.35. The firm has a market capitalization of $30.15 billion, a PE ratio of 46.22, a P/E/G ratio of 2.46 and a beta of 1.12.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.